Dentsply sues law firm over $15M breach-of-contract loss | Legal News

Lewis & Roca

Dentsply International (NSDQ:XRAY) sued the law firm that represented it in a breach-of-contract lawsuit filed against it by Guidance Endodontics that wound up costing Dentsply more than $15 million.

Guidance sued Dentsply for breach of contract in 2008 over a supply deal for dental obturators, endodontic files and ovens. The case went to trial in the fall of 2009, with Thomas Gulley of the firm Lewis & Roca representing Dentsply. The jury returned a verdict against the York, Pa.-based dental devices maker, awarding more than $4 million for the breach of contract, punitive damages of $40 million and legal fees of more than $3.5 million, according to court documents. The judge in the case later reduced the punitive damages to $4 million, according to the documents.

Now Dentsply wants the law firm to pony up $15 million in compensatory damages for its alleged malpractice, arguing that Lewis & Roca and Gulley "failed to develop a theory of the case prior to trial," "failed to conduct adequate and appropriate discovery," "failed to retain appropriate experts or elicit necessary expert
testimony," "failed to object to erroneous jury instructions and invited error," "failed to make appropriate motions" and "failed to preserve key issues for appeal," according to the lawsuit.

"As a direct and proximate result of defendants’ professional negligence, breach of contract, and breaches of the applicable standard of care and fiduciary duties, Guidance obtained a verdict against clients in excess of $44 million dollars, and clients sustained damages in excess of $15 million dollars," according to the suit.

 Hansen settles shareholder suits

Hansen Medical (NSDQ:HNSN) agreed to pay $300,000 to settle a set of lawsuits filed against by shareholders over a 2009 financial restatement.

Hansen adjusted its books in 2009 after receiving an anonymous tip that "documentation related to certain revenue transactions was falsified, and there was not an effective control environment in our sales, clinical and field service departments," according to regulatory filings. The company had recognized revenues for the sale of 2 of its Sensei robotic surgery systems but had in fact received only $320,000.

"As a result, there were instances where revenue was recognized prior to the completion of all of the elements required for revenue recognition under our revenue recognition policy. All of the irregularities that were identified during the investigation occurred outside of the accounting department," according to the filings.

The restatement pushed Hansen’s losses during the 3 months ended Sept. 30, 2008, from $12.0 million, or 48 cents per share, to $12.9 million, or 51 cents per share.

Shareholder lawsuits soon followed, alleging that the company and its management "made false and/or misleading statements and/or failed to make disclosures regarding our financial results and compliance with [generally accepted accounting principles] while improperly recognizing revenue; that these misstatements and/or non-disclosures resulted in overstatement of our revenue and financial results and/or artificially inflated our stock price; and that following our October 19, 2009 announcement, the price of our stock declined," according to filings with the SEC.

HNSN shares plunged 9% that day, from an Oct. 16, 2009, close of $3.43 to end the next day at $3.12.

Now the company says it’s agreed to cover the plaintiffs’ legal fees, to the tune of $300,000, and institute safeguards to prevent a recurrence of the problem. Read more

 DePuy Pinnacle lawsuits top 900

More than 900 personal injury lawsuits have been filed over a hip implant made by Johnson & Johnson (NYSE:JNJ) subsidiary DePuy, according to a law firm representing some of the plaintiffs.

The cases were filed over DePuy’s Pinnacle metal-on-metal hip replacement implant, which been found to shed minute particles of metal as the hip’s ball joint wears on its metal cup. The lawsuits allege that increases the risk of problems and make the implants prone to early failure.

The cases were consolidated in the U.S. District Court for Northern Texas by the U.S. Judicial Panel on Multidistrict Litigation last year, under Judge James Kinkeade. Read more

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]

Leave a Reply